HIGHER Corporation, a pioneering medical device startup, has been distinguished as a 'Baby Unicorn' by the Ministry of SMEs and Startups, alongside receiving the 'First Penguin' accolade from the Korea Credit Guarantee Fund. These recognitions affirm the company's cutting-edge technology and robust business model, earmarking it as a future global unicorn. The 'Baby Unicorn' initiative is a strategic government effort to foster startups with high global growth potential, offering them financial support, strategic guidance, and market development opportunities.
The company's flagship product, HILO WAVE®, represents a breakthrough in bio-stimulation technology. Utilizing a dual-formulation of hyaluronic acid, it enhances skin elasticity and hydration by stimulating natural collagen and elastin production, distinguishing itself from traditional volume-adding fillers. Approved as a Class 4 medical device in Korea, HILO WAVE® has garnered trust among medical professionals for its safety and efficacy.
HIGHER Corporation's global expansion is already underway, with substantial supply contracts in Southeast Asia and active negotiations in Brazil and China, projecting over 20 billion KRW in contracts. The company is also pursuing CE MDR certification to penetrate the European market, further solidifying its international presence. This global strategy, supported by the Korean government's financial and logistical backing, positions HIGHER Corporation as a formidable player in the aesthetic medical device industry, with the ambition to lead as a global unicorn.
